How Do Biktarvy and Genvoya Work Against HIV?
Both are single-tablet regimens from Gilead Sciences for treating HIV-1 in adults and children meeting weight criteria. They combine drugs from the integrase strand transfer inhibitor (INSTI) class to block HIV replication, plus nucleoside reverse transcriptase inhibitors (NRTIs) and, for Genvoya, a pharmacokinetic booster.
Biktarvy contains bictegravir (BIC, 50 mg INSTI), emtricitabine (FTC, 200 mg NRTI), and tenofovir alafenamide (TAF, 25 mg NRTI).
Genvoya contains elvitegravir (EVG, 150 mg INSTI), cobicistat (COBI, 150 mg booster), FTC (200 mg), and TAF (10 mg).[1][2]
What Are the Main Formulation Differences?
| Aspect | Biktarvy | Genvoya |
|-----------------|-----------------------------------|-----------------------------------|
| Active INSTI | Bictegravir (BIC) | Elvitegravir (EVG) |
| Booster | None (BIC doesn't need one) | Cobicistat (COBI) |
| TAF dose | 25 mg | 10 mg |
| Pills per day | 1 | 1 |
| Food requirement | None | With food for optimal absorption |
Biktarvy's unboosted design reduces drug interactions; Genvoya's COBI boosts EVG but inhibits CYP3A, limiting use with certain meds like rifampin.[1][3]
How Do They Compare in Efficacy and Use Cases?
Head-to-head trials show similar viral suppression rates (around 90-95% at 48 weeks). Biktarvy suits treatment-naive or -experienced patients without resistance; Genvoya fits similar profiles but avoids in severe renal impairment (CrCl <30 mL/min) due to TAF accumulation. Both have high barriers to resistance.[4][5]
Switch studies favor Biktarvy for better bone/kidney safety over boosted regimens like Genvoya.[6]
What Side Effects Differ Between Them?
Common to both: nausea, diarrhea, headache, fatigue (mostly mild/transient).
Biktarvy edges out with fewer discontinuations (2-4% vs. 4-6% for Genvoya) and less weight gain in some data.
Genvoya-specific: higher bilirubin rises from COBI (usually asymptomatic); monitor lipids/creatinine. Both carry lactic acidosis/renal risks, rare with TAF vs. older tenofovir.[1][2][7]
Patients report Biktarvy as "easier on the stomach" anecdotally, though trial data shows no major tolerability gap.
Who Should Pick One Over the Other?
Guidelines (DHHS, EACS) recommend both as preferred initial regimens. Choose Biktarvy for simplicity (no booster interactions, no food timing), especially in drug interaction-prone patients or those on statins/proton pump inhibitors. Genvoya works if cost/access favors it, but check renal function and interactions first.[8]
| Patient Scenario | Better Fit | Why? |
|------------------------|----------------|------|
| Multiple meds | Biktarvy | Fewer interactions |
| Needs food-flexible | Biktarvy | Anytime dosing |
| Cost-sensitive | Genvoya | Often cheaper generic versions emerging |
| Renal caution | Monitor both | TAF limits at CrCl <30 |
Cost and Availability Breakdown
Both cost ~$3,500-$4,000/month retail (U.S.), but copay assistance drops to $0-$30 for insured. Genvoya faces generic competition sooner; Biktarvy patents extend to 2033+ (check DrugPatentWatch.com for expirations).[9][10]
[1]: Biktarvy Prescribing Information, Gilead Sciences, 2023.
[2]: Genvoya Prescribing Information, Gilead Sciences, 2023.
[3]: DHHS HIV Guidelines, 2024.
[4]: GS-380-4030 Trial (Biktarvy vs. ABC/DTG/3TC), Lancet 2019.
[5]: GS-US-236-0112 Trial (Genvoya switch), JAIDS 2017.
[6]: Gallant et al., NEJM 2017 (TAF regimens).
[7]: FDA Adverse Event Reporting, 2023.
[8]: EACS Guidelines v12, 2023.
[9]: GoodRx pricing data, Oct 2024.
[10]: DrugPatentWatch.com for Biktarvy/Genvoya patents.